Autonomix Medical (NASDAQ:AMIX) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Autonomix Medical (NASDAQ:AMIX) from a sell rating to a strong sell rating in a report published on Monday morning,Wall Street Zen reports.

Several other research firms have also commented on AMIX. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Autonomix Medical currently has an average rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Price Performance

Shares of AMIX opened at $4.33 on Monday. The firm has a market capitalization of $4.20 million, a P/E ratio of -0.10 and a beta of -1.00. Autonomix Medical has a one year low of $2.44 and a one year high of $32.55. The business has a fifty day moving average of $5.87 and a 200 day moving average of $7.29.

Autonomix Medical (NASDAQ:AMIX) last posted its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. Analysts expect that Autonomix Medical will post -20.17 EPS for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.